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Background: Multipotent mesenchymal stem/stromal cells (MSC) including adipose-derived stromal cells (ADSC)
have been successfully applied for cardiovascular diseases treatment. Their regenerative potential is considered due
to the multipotency, paracrine activity and immunologic privilege. However, therapeutic efficacy of autologous MSC
for myocardial ischemia therapy is modest. We analyzed if ADSC properties are attenuated in patients with chronic
diseases such as coronary artery disease (CAD) and diabetes mellitus type 2 (T2DM).
Methods and results: ADSC were isolated from subcutaneous fat tissue of patients without established
cardiovascular diseases and metabolic disorders (control group, n = 19), patients with CAD only (n = 32) and
patients with CAD and T2DM (n = 28). ADSC phenotype (flow cytometry) was CD90+/CD73+/CD105+/CD45−/CD31−
and they were capable of adipogenic and osteogenic differentiation. ADSC morphology and immunophenotype
were similar for all patients, but ADSC from patients with CAD and T2DM had higher proliferation activity and
shorter telomeres compared to control patients.
ADSC conditioned media stimulated capillary-like tubes formation by endothelial cells (EA.hy926), but this effect
significantly decreased for patients with CAD (p = 0.03) and with CAD + T2DM (p = 0.017) compared to the control
group. Surprisingly we revealed significantly higher secretion of some pro-angiogenic factors (ELISA) by ADSC: vascular
endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) for patients with CAD and HGF and placental
growth factor (PlGF) for patients with CAD + T2DM. Among angiogenesis inhibitors such as thrombospondin-1,
endostatin and plasminogen activator inhibitor-1 (PAI-1) level of PAI-1 in ADSC conditioned media was significantly
higher for patients with CAD and CAD + T2DM compared to the control group (p < 0.01). Inhibition of PAI-1 in ADSC
conditioned media by neutralizing antibodies partially restored ADSC angiogenic activity (p = 0.017).
Conclusions: ADSC angiogenic activity is significantly declined in patients with CAD and T2DM, which could restrict
the effectiveness of autologous ADSC cell therapy in these cohorts of patients. This impairment might be due to the
disturbance in coordinated network of pro- and anti-angiogenic growth factors secreted by ADSC. Changes in
ADSC secretome differ between patients with CAD and T2DM and further investigation are necessary to reveal the
MSC-involved mechanisms of cardiovascular and metabolic diseases and develop novel approaches to their correction
using the methods of regenerative medicine.
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Cardiovascular diseases are the most frequent causes of
death globally. The prevalence of metabolic disorders, first
of all diabetes mellitus type 2, is similar to epidemic and
greatly increases every year. Most of cardiac pathologies
as well as T2DM result in permanent cardiac tissue dam-
age followed by heart failure [1-4]. Current therapies pri-
marily aim to treat the pathological remodeling of the
heart that occurs after cardiac injury. However, there is a
group of patients with refractory angina and heart failure
that are incurable despite advances in medical treatment
and surgical and percutaneous interventions. The attempt
to find new treatment for these patients leads researchers
to investigate the approaches of regenerative medicine
using autologous and allogeneic stem cells.
Multipotent mesenchymal stromal cells (MSC) have
been used in many animal and human studies and serve
as an attractive candidate for tissue engineering and cell-
based therapies. The neovascular potential of MSC is
mostly supported by their ability to secrete potent pro-
angiogenic growth factors and cytokines [5-8]. MSC can
be derived from different tissue including bone marrow,
adipose tissue, cord blood and umbilical cord, endome-
trium and some others. One of the most clinically rele-
vant source of MSC is adipose tissue where these cells
are located in perivascular niche [9-11]. There are
numerous experimental studies and clinical trials which
demonstrated the perspectives of using the adipose-
derived stromal cells (ADSC) for the cure of different
diseases [12-18]. ADSC are easily harvested, readily
available and abundant in high numbers for the transplant-
ation. In addition, soluble growth factors and cytokines se-
creted by ADSC may directly initiate vessels growth,
branching and maturation, and also induce the release of
angiogenic factors from other cell types [17,19-22]. In the
perspective of cell-based therapeutic angiogenesis, there
have been several clinical trials (ADVANCE, PRECISE,
MyStromalCell Trial) that have showed some beneficial
effects of ADSC therapy in patients with cardiovascular
diseases [7,8,23,24]. However, overall therapeutic efficacy
of the autologous MSC based cell therapy for the treat-
ment of cardiovascular diseases is modest. It could be
caused by the attenuation of MSC angiogenic potential in
patients due to different risk factors affecting the stem and
progenitor cell compartment. Some chronic diseases by
itself also could attenuate MSC regenerative properties. In
the present study we analyzed how ADSC properties are
changed in patients with CAD and T2DM.
Materials and methods
Ethics statement
All procedures performed with tissue samples from pa-
tients were approved by Ethic Committee of the Russian
Cardiology Research and Production Center. Eachindividual participate in the study signed a written in-
formed consent for harvesting and using adipose tissue
samples as well as for handling clinical data for research
purposes.
Patients
Nineteen patients without established cardiovascular dis-
eases were included in the control group. They were
underwent surgery because of general surgical pathology
or endoprosthesis replacement of femoral or knee joints.
Sixty patients who underwent coronary artery bypass
grafting were divided into two groups of people with
CAD only and with CAD + T2DM.
Exclusion criteria included autoimmune pathologies,
cancer (even in the past history), acute or chronic inflam-
matory disease, acute myocardial infarction in the previous
six months, long-termed hormone or antibiotics therapy,
anemia (Hb < 10 g/dl) and hematological disorders, stroke
or craniocerebral injury in the previous 12 months. Ad-
ditional special exclusion criteria for the control group
were any evidence for cardiovascular diseases and diabetes
(based on standard clinical examination), including myo-
cardial infarction or myocarditis, clinical signs of angina or
heart failure, arrhythmias such as paroxysmal or per-
manent form of atrial fibrillation, frequent premature ven-
tricular complexes, paroxysmal ventricular tachycardia,
left bundle branch block, clinical manifestation of systemic
atherosclerosis, severe dyslipidemia. Patients of both sexes
were included in the study, but all women were under the
post-menopause period and none of them received hor-
monal replacement therapy.
Clinical data acquisition and analysis
Hospital in-patient databases were used to obtain clinical
data including medical history, demographic characteris-
tics (gender, age), diagnostic results, laboratory blood
tests and medical treatment (Table 1). The body mass
index (BMI) was calculated as the individual’s body mass
divided by the square of his or her height (unit of mea-
sure of kg/m2). Data were interpreted as follows: normal
if < 25, overweight if ≥ 25 and < 30, and obesity if ≥ 30.
Severity of angina pectoris was estimated according
to the criteria of the Canadian Cardiovascular Society
Classification (CCSC) based on the extent of limitation
on daily activities and the kind of physical activity which
interrupted by the angina episode. Functional assess-
ment of heart failure symptoms was made according to
New York Heart Association (NYHA) classification. This
system relates symptoms to everyday activities and the
patient’s quality of life. All patients with CAD underwent
left heart catheterization, left ventriculography and cor-
onary angiography according to the guidelines for coro-
nary angiography of the American College of Cardiology
and the American Heart Association. Cardiac function
Table 1 Clinical characteristics of patients with coronary artery disease and diabetes mellitus type 2
Clinical characteristics Groups of patients p
Control CAD CAD +DM2
Number of patients 19 32 28 -
Age, years 56,7 ± 12,3 62,3 ± 8,6 61,0 ± 8,2 NS
Gender, male, n (%) 5 (26,3%) 29 (90,6%) 17 (60,7%) <0,05
Functional class of stable angina, n (%) - II FC-8 (25%), II FC-5 (18%), NS
III FC - 13 (41%), III FC-9 (32%),
IV FC – 11 (34%) IV FC-14 (50%)
MI in past history, n (%) - 20 (63%) 18 (64%) NS
The score of coronary artery atherosclerosis, n (%) - 2CA-6 (18,8%) 2CA-5 (17,9%) NS
3CA-26 (81,3%) 3CA-23 (82,1%)
Ejection fraction (%) 57,8 ± 1,8 55,0 ± 9,8 58,0 ± 9,2 NS
Arterial hypertension, n (%) 3 (15,8%) 27 (84%) 24 (86%) <0,05
Obesity, n (%) 12 (63%) 20 (63%) 19 (68%) NS
BMI, kg/m2 28,6 ± 3,7 30,6 ± 0,8 28,14 ± 1,07 NS
Total protein, g/l 68,7 ± 1,9 69,4 ± 1,6 72,1 ± 3,2 NS
Glucose, mmol/l 5,46 ± 2,2 5,4 ± 3,2 10,1 ± 4,1 <0,05
Triglyceride, mmol/l 1,7 ± 1,3 2,1 ± 1,1 1,9 ± 0,9 NS
Cholesterol, mmol/l 4,4 ± 0,4 4,5 ± 0,4 4,9 ± 0,9 NS
Urea, mmol/l 5,9 ± 0,8 6,2 ± 0,5 9,02 ± 1,5 NS
Creatinine, ummol/l 68,8 ± 9,5 66,6 ± 7,5 139,8 ± 23,2 <0,01
Medical treatment before CABG
β-blockers, n (%) - 27 (84%) 23 (82%) NS
Antiplatelet agents, n (%) - 32 (100%) 28 (100%) NS
Statins, n (%) - 28 (88%) 25 (89%) NS
ACE inhibitors, n (%) - 20 (63%) 18 (64%) NS
Calcium antagonists, n (%) - 13 (41%) 12 (43%) NS
Diuretics, n (%) - 23 (72%) 21 (75%) NS
Nitrates, n (%) - 27 (84%) 23 (82%) NS
FC – Functional class, BMI – Body mass index, CABG – Coronary artery bypass grafting, p – p-value for multiple comparison of patient’s groups, NS – Non-significant.
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was estimated using respective software for different
cardiac ultrasound systems: Vivid 7 (GE Ultrasound,
Horten, Norway) and Philips-iE33 (Philips Medical Systems,
Andover MA, USA). The extent of coronary artery athero-
sclerosis was scored as 0 (stenosis < 50%), 1 (stenosis of
any main coronary artery > 50%), 2 (stenosis of two main
coronary arteries >50%), and 3 (stenosis of three main
coronary arteries > 50%).
Isolation of adipose-derived stromal cells
Subcutaneous adipose tissue samples (0,5-5 ml) harvested
during surgery were homogenized and digested in collage-
nase I (200 U/ml, Worthington Biochemical) and dispase
(40 U/ml, Sigma) solution under agitation for 30–40 min
at 37°C. Then tissue was centrifuged at 200 g for 10 min
and the supernatant discarded. The pellet containingADSC was lysed to destroy erythrocytes, filtered through
a sieve (BD Falcon Cell Strainer, 100 mkm) and centri-
fuged at 200 g for 10 min. The final pellet was resus-
pended in culture medium. The cells were cultured in
standard conditions (5% СО2; 37°С) in Advance Stem Cell
Basal Medium (ADSCBM, HyClone) with 10% of Advance
Stem Cell Growth Supplement (HyClone), 100 U/ml peni-
cillin/streptomycin and 100 U/ml fungisone (HyClone). In
24 hours after isolation non-attached cells were washed
off, and then medium was changed every 3–4 days. Cells
yield was 4-7×104 of attached cells/ml of tissue.
Collection of ADSC conditioned medium
ADSC were harvested, using HQtase (HyClone), counted,
washed by PBS and centrifuged at 4°C. Then ADSC pellet
samples for RNA extraction were frozen in liquid nitrogen
and stored at −70°С.
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fluence in culture dishes, then washed extensively with
PBS, and replenished with supplement-free Advance
Stem Cell Basal Medium for 48 hours. Collected media
samples were centrifuged at 3,000 rpm for 10 min at 4°C
to remove cell debris, and filtered through a 0.2 mm
filter. Then conditioned medium was collected, supple-
mented with Protease Inhibitor Cocktail (1:500, Sigma)
and frozen in aliquots at −70°С.
ADSC surface markers expression analysis by flow
cytometry
Cells were harvested with 2 mM EDTA/PBS and stained
with antibodies against CD34 (BD Pharmingen), CD45
(BD Pharmingen), CD73 (BD Pharmingen), CD90 (BD
Pharmingen), CD105 (BD Pharmingen), neuro-glial pro-
teoglycan 2 (NG2, Chemicon), platelet-derived growth
factor receptor B (PDGFRB, BD Pharmingen) conjugated
with different fluorochromes, in appropriate conditions.
Matching isotype control antibodies were used as nega-
tive control. The cells were analyzed using cell sorter
MoFlo (Dako Cytomation).
Differentiation
For osteogenic differentiation 60000 ADSC were seeded
in collagen-coated 24-well plates with medium contai-
ning 10−8 M dexamethasone, 10 mM β-glycerol-2-phos-
phate and 5 μg/ml ADSCorbic-2-phosphate (Invitrogen)
for 21 days. Mineralization of ECM was evaluated by
staining with Alizarin Red S (40 mM, pH 4,2) (Sigma).
For adipogenic differentiation 60000 ADSC were seeded
in 24-well plates with induction medium containing 10−6 M
dexamethasone, 10 μM insuline, 200 μM indomethacine,
0,5 mM 3-isobutil-1-methylxantine (Invitrogen) for 6 days,
then medium was changed to insulin-containing medium
(10 μM) for 3 days followed by culturing in induction
medium for 6 days. After 14 days of stimulation adipo-
genic differentiation was confirmed by Oil Red O staining
for visualization of lipid droplets (Sigma).
ADSC from the same patient cultured in standard con-
ditions without stimulation served as negative control.
Proliferation
Proliferation of ADSC was evaluated using labeling with
vital dye CFSE (Molecular Probes) according to manu-
facturer instructions. Its amount was diminished twice
with every cell division. After 5 days labeled cells were
analyzed by cell sorter MoFlo (Dako Cytomation) and
their proliferation activity was determined using a spe-
cific formula as x1*1 + x2*2 +….xn*n where xn – percen-
tage of cells in total population divided n times during
5 days.
At passage 1–2 the expansion of ADSC was also ana-
lyzed by using the trypan blue exclusion method. Thenumber of PD (population doubling) was calculated by
dividing the logarithm of the fold increase yield obtained
at the end of the passage by the logarithm of 2.
Relative telomere length measurement by quantitative
real-time PCR (qRT-PCR)
DNA was isolated using Qiagen DNeasy Mini Kit (Qiagen)
and concentration was measured at NanoDrop200 (Peqlap).
Telomere length was measured by qRT-PCR and norma-
lized to telomere length in HeLa cells [25].
Quantitative telomerase activity assay
Cell pellets were resuspended in lysis buffer and ana-
lyzed with qRT-PCR using the quantitative telomerase
detection kit (QTD, US Biomax) according to manufac-
turer instructions. Protein concentration was determined
with the BCA Protein assay (Pierce). Telomerase activity
of ADSC was expressed relative to HeLa cells and nor-
malized to protein concentration for every sample. “Heat
control” samples incubated for 15 minutes at 85°C
served as negative control.
Relative gene expression measured by qRT-PCR
Total RNA was isolated using RNase Mini Kit (Qiagen)
followed by a reverse transcription reaction with Fermentas
Reverse Transcription Reagents (Fermentas). RT-PCR
was performed using SYBR Green PCR Master Mix
(EuroGene) using BIO-RAD iQ5 Multicolor Real-time
PCR detection system (Bio-Rad). PCRs in duplicates for
every sample were performed in a final volume of 25 μl
reaction mix that contained 50 ng of cDNA product,
100 nmol/L of each primer. For all reactions thermal cycling
parameters were: 10 minutes at 95°C followed by 40 cycles
of 15 seconds at 95°C, 20 seconds at 59-61°C depended on
using primer and 20 seconds at 72°C. The oligonucleotides
used as primers (EuroGene) are listed in Additional file 1:
Table S1. GAPDH and β-actin were used as reference genes.
Analysis of angiogenic factors accumulation in ADSC
conditioned medium by ELISA
The conditioned media were analyzed for accumulation
of vascular endothelial growth factor (VEGF), placental
growth factor (PlGF), hepatocyte growth factor (HGF),
angiopoetin-1 (ANG-1), angiogenin, thrombospondin-1
(THBS1) and plasminogen activator inhibitor-1 (PAI-1)
using ELISA (R&D Systems) according to manufacturer
instructions. Level of every protein was normalized to cell
concentration for every sample of conditioned medium.
In vitro tube formation assay
Effect of ADSC conditioned medium on capillary-like
tubes formation on Matrigel in vitro was evaluated. En-
dothelial cells EA.hy926 [26] were seeded in 96-well
plates coated with growth factor reduced Matrigel (BD
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conditioned media were added. Three wells were used for
each sample of conditioned medium. Supplement-free
ADSC basal medium was utilized as a negative control;
ADSC basal medium with 20% of Supplement served as
positive control. For the blocking of PAI-1 effect the spe-
cific neutralizing antibodies (R&D Systems, 5 mkg/ml)
were added to the corresponding wells. Plates were placed
into CO2-incubator at 37°C and capillary-like structures
were assayed in 24 hours under the light microscope
(Leica, Germany). Total length of tubular structures was
counted in 5 random fields of view per well (objective
10×) using MetaMorph 5.0 software (Universal Imaging).
This parameter was used to characterize angiogenic ac-
tivity of ADSC summary secreted products in vitro.
Statistical analysis
Statistical analysis was performed using Statistica 8.0
software. Values are expressed as mean ± standard error
of mean (SEM) for normally distributed data and median
and percentiles (25%-75%) for not normal data. If nor-
mality of data was confirmed (according to Kolmogorov-
Smirnov test and Shapiro-Wilk’s W test) comparison of
independent groups was performed by Student t-test, if
not or size of the analyzed sample was less than 10 cases –
by Mann–Whitney U-criteria. Multiple comparisons were
made using one-way ANOVA for normally distributed
data, otherwise - by Kruskall-Wallis test. For dependent
group comparisons the Wilcoxon rank sum test was used.
For comparison of nominal variables distribution chi-
square method was used. Correlation analysis was per-
formed using Pearson correlation if both analyzed samples
were normally distributed, otherwise Spearman corre-
lation was applied. Statistical significance was defined as
p-value <0.05 and all reported statistical tests were two-
tailed.
Results
Clinical characteristics of the patients included in the
study
In total, 79 patients were included in the study. The data
of patients with cardiovascular diseases and T2DM are
presented in Table 1. Nineteen patients from the control
group didn’t have established cardiovascular diseases
and metabolic disorders. The average age was 55,9 ± 2,3
(control group), 61,9 ± 8,9 (CAD), 61,3 ± 1,8 (CAD +
T2DM) years and the differences between groups were
not significant. There was a significant difference in the
number of women between the control group (68,4%)
and diseased patients (13% in CAD, 40% in CAD +
T2DM). It is important to note that all women in the
study were under the post-menopause period, and none
of them received hormonal replacement therapy. How-
ever, to avoid the interference of gender differencesbetween groups we compared the results obtained from
men and women within every group of patients.
There were several obvious differences in characteris-
tics of patients with CAD according to the presence or
absence of T2DM. In particular, diabetic subjects had
higher glucose and lower creatinine clearance in com-
parison to the patients with CAD only. Among the dia-
betic subjects 28% were on oral anti-diabetic agents
only, 49% were on insulin with or without oral agents
and 23% were on only anti-diabetic diet. Among the pa-
tients there was no difference in smoking, hypertension,
BMI and the use of antiplatelet agents, statins, ACE in-
hibitors, beta-blockers, calcium channel blockers and
nitrates.
ADSC from patients with CAD and T2DM keep MSC
characteristics
Culturing of cells harvested from adipose tissue as de-
scribed above in the medium supported growth of undif-
ferentiated mesenchymal stem cells allows to get at the
2nd-3rd passages a relatively homogenous population of
fibroblast-like cells with characteristics of MSC We
assessed changes in cellular morphology of ADSC from
patients with different pathologies through the first three
passages. Under microscopic examination all the adhe-
rent cells displayed similar fibroblast-like spindle-shaped
morphology. ADSC were examined by flow cytometry
(Additional file 2: Figure S2, Additional file 3: Figure S3)
and were found to be positive for CD73 (>85%), CD90
(>95%) and CD105 (>95%) with no or low expression of
CD14 (<10%), CD19 (<10%), CD34 (<5%), CD45 (<1%),
CD79 (<10%). ADSC also expressed pericyte markers
like NG2 (>95%) and PDGFRB (>80%). Therefore, ADSC
from healthy donors as well as from patients with CAD
and T2DM express the minimal required immunophe-
notype criteria according to the International Society for
Cellular Therapy Statement of minimal criteria for de-
fining MSC [27].
One of the defining characteristics of MSC is an ability
to differentiate into adiposytes, osteoblasts and chon-
droblasts. ADSC both from the patients without cardio-
vascular diseases and patients with CAD and/or T2DM
demonstrated bone mineralization and neutral lipid accu-
mulation in the appropriate culture medium and condi-
tions, thus confirming the multipotent nature of ADSC
obtained from investigated patients (data not shown).
The effect of chronic pathologies on ADSC population
doublings (PD) was calculated. We didn’t observe signifi-
cant changes in the number of PD (passage 1–2) between
ADSC obtained from patients with CAD (1,68 ± 0,08) and
CAD+T2DM (1,53 ± 0,11) compared to the control
group (1,47 ± 0,07), although there was a tendency to the
increasing PD of ADSC from patients with CAD com-
pared to the control patients (p = 0,11). In order to
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populations of ADSC changed in the presence of CAD
and T2DM we labeled cells with vital fluorescent dye
CFSE and analyzed ADSC distribution according to CFSE
intensity by flow cytometry. We couldn’t reveal any sig-
nificant differences between studied groups of patients in
ratio of active and slow proliferating cells subpopulations
among the whole ADSC population, but we found that
general proliferation activity of ADSC from patients with
CAD and CAD+T2DM significantly increased compared
to the control group (Figure 1A).
Proliferation activity of cells is closely related to the
telomere length and telomerase activity. We evaluated
relative telomere length and telomerase activity in ADSC
from patients with and without CAD and T2DM. We
observed significant decrease of the relative telomere
length in ADSC from patients with CAD and T2DM com-
pared to the patients from the control group (Figure 1B).
We also measured telomerase activity in ADSC and de-
tected it in all analyzed cell samples at the level about
5-fold lower than in HeLa cells. Measurement of telo-
merase activity in ADSC didn’t reveal significant changes
between patients from different groups, probably because
of high variability between samples. But there was no sig-
nificant association detected between telomerase activity
and relative telomere length in all groups of patients.
ADSC from patients with CAD and T2DM have impaired
ability to stimulate angiogenesis in vitro
Considering that the ability of ADSC to stimulate blood
vessel growth is mainly mediated by paracrine mecha-
nisms through the production of various angiogenic fac-
tors by these cells we analyzed angiogenic activity of
summary products secreted by ADSC on the model of
capillary-like tubes formation by endothelial cells on
Matrigel. We found that ADSC conditioned media stim-
ulated capillary-like tubes formation by endothelial cells





























Figure 1 ADSC from patients with chronic ischemic pathologies and m
telomeres compared to the control group. (A) Proliferation activity of A
**p = 0,046. (B) Relative telomere length in ADSC measured by RT-PCR, datpatients with CAD (p = 0.03) and with CAD + T2DM
(p = 0.017) compared to the control group (Figure 2).
There were no significant differences in ADSC angio-
genic activity in vitro between from patients with CAD
only and with CAD + T2DM (Figure 2). We also didn’t
find any significant differences in angiogenic activity
in vitro of ADSC obtained from men and women within
every studied group.
To reveal which angiogenic factors are involved in de-
creasing of angiogenic activity of ADSC summary secreted
products in vitro in the presence of CAD and T2DM we
analyzed gene expression of various angiogenesis-related
factors in ADSC by real-time PCR. Surprisingly, we found
that gene expression of such key proangiogenic factors as
VEGF, PlFG and HGF was significantly increase in ADSC
from patients with CAD and CAD+T2DM compared to
the control group (Figure 3A,B,C). At the same time we
didn’t observe significant disease-associated changes in
gene expression of basic fibroblast growth factor (bFGF),
angiopoetin-1, and angiogenin (data not shown).
Considering that level of secreted factors is more essen-
tial for paracrine effects of ADSC on angiogenesis we eva-
luated accumulation of these pro-angiogenic factors in the
conditioned medium from ADSC. We found that ADSC
obtained from patients with CAD secreted significantly
higher amounts of VEGF and HGF and ADSC obtained
from patients with CAD+T2DM secreted more PlGF and
HGF compared to the control group which was consis-
tent with the results of gene expression analysis (Table 2,
Figure 3D,E,F). As for other angiogenic factors such as
angiopoetin-1 and angiogenin we didn’t find significant
changes in level of their secretion by ADSC dependent on
the presence of CAD and T2DM (Table 2).
To explain the obvious discrepancy between the re-
sults of ADSC angiogenic activity in vitro assay and an-
giogenic factor production by these cells we considered
that in the process of tissue regeneration, angiogenesis






























etabolic disorders proliferate more actively and have shorter
DSC evaluated by CFSE assay, data are mean ± SEM, *p = 0,048,
a are median and percentiles (25%-75%), *p < 0,0001, **p = 0,0004.
Figure 2 Angiogenic activity in vitro of the summary products secreted by ADSC obtained from patients with CAD and DM2 decreased
compared to the control group. (A) Representative microphotographs of capillary-like tubes formed by EA.hy 926 endothelial cell line on Matrigel in
the presence of ADSC conditioned media from the control group patient, patient with CAD and patient both with CAD and DM2. (B) Total tube
length measurement for ADSC obtained from the patients with different pathologies, data are median and percentiles (25-75%), *p = 0,03, **p = 0,017.
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we analyzed the production of some angiogenesis inhibi-
tors by ADSC from patients with different pathologies
such as endostatin (ENDS) and thrombospondin-1
(THBS-1). We showed significant increase in mRNA
level of THBS-1 in ADSC obtained from patients with
CAD and with CAD + T2DM (Figure 4A). However, we
failed to show the increase in the content of THBS-1 in
the conditioned media of ADSC from the same patients
(Table 2, Figure 3B). At the same time statistical analysis
revealed negative correlation between mRNA level of
TBHS1 in ADSC and their angiogenic activity measured
by the tube formation assay in the group of patients with
CAD (r = −0,59, p = 0,045) and in the group of patients
with CAD + T2DM (r = −0,7, p = 0,008). As for ENDS
we couldn’t find any significant differences both in
mRNA level and protein secretion between ADSC ob-
tained from patients with cardiovascular diseases and
control subjects.PAI-1 suppresses in vitro angiogenic activity of ADSC
from patients with CAD and T2DM
Apart from angiogenic growth factors effects extracel-
lular matrix (ECM) remodeling is crucial for successful
angiogenesis. ECM remodeling as well as directed cell
migration for incorporation into forming vessel wall are
regulated by some factors such as urokinase (uPA) and
its receptor (uPAR), PAI-1 and matrix metalloproteases
(MMP). Analyzing the gene expression of uPA, uPAR
and PAI-1 in ADSC we found that mRNA level of PAI-1
was significantly increased in ADSC from patients with
CAD and CAD + T2DM compared to control subjects
(Figure 5A). These results were accompanied by data of
ELISA which revealed higher concentration of PAI-1 in
ADSC conditioned media obtained from the same patients
in comparison to the control group (Table 2, Figure 5B).
To reveal the impact of PAI-1 to the angiogenic acti-
vity of ADSC summary secreted products in vitro we









































































































Figure 3 Pro-angiogenic growth factor production by ADSC from patients with chronic ischemic pathologies and metabolic disorders
was higher compared to the patients of the control group. (A-C) Gene expression of VEGF (A), PlGF (B) and HGF (C) in ADSC obtained
from the patients with CAD, CAD + DM2 and the control group. Y-axis: mRNA level in ADSC, relative units. (D-F) Concentration of VEGF (D), PlGF
(E) and HGF (F) in ADSC conditioned medium. Y-axis: Protein content in ADSC conditioned medium, ng/mln. of cells. Data are median and
percentiles (25-75%), p-values are presented on the graphs.
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evaluating their ability to stimulate capillary-like tube
formation (Figure 5C,D). We found that PAI-1 blocking
in ADSC conditioned medium partially, but significantly
restored the angiogenic activity of summary products
secreted by ADSC from patients with cardiovascular
pathology and diabetes (Figure 5E).Table 2 Accumulation of angiogenic factors in ADSC conditio
Growth factor Groups of patients
Control CAD
VEGF 6,55 (2,9-13,8) 12,3 (5,
HGF 1,19 (0,76-2,2) 3,25 (2,
PlGF 0,04 (0,02-0,07) 0,07 (0,0
Angiogenin 1,62 (0,9-2,9) 1,8 (0,52





*p-value for CAD group vs. the control group; **p-value for CAD + T2DM group vs.
type 2; NS- Non significant.Discussion
MSC, including ADSC, have been recently recognized as
an attractive source of adult stem and progenitor cells
for cell therapy and tissue engineering. Although the re-
generative effects of these cells have been actively stu-
died in various experimental models and clinical trials,
little is known about the influence of chronic pathologiesned media (ng/mln. of cells) measured by ELISA
CAD + T2DM p-value
6-20,3) 7,52 (3,3-19,3) *p = 0,045
0-5,5) 2,83 (2,12-4,75) *p = 0,021
**p = 0,004
3-0,16) 0,24(0,08-0,28) **p = 0,014
-2,47) 0,74 (0,56-2,6) NS
8-1,7) 0,39 (0,18-0,67) NS
142,22 *p = 0,0013
22,8) (45,0-268,5) **p = 0,0053
254,4 NS
2,1) (85,1-421,8)





































































Figure 4 Thrombospondin-1 (THBS-1) production by ADSC from patients with chronic ischemic pathologies and metabolic disorders
compared to the control group. (A) Gene expression of THBS-1 in ADSC obtained from the patients with CAD, CAD + DM2 and the control









































































Figure 5 Impact of PAI-1 to the decline of the angiogenic activity of ADSC obtained from the patients with CAD and CAD +DM2.
(A-B) PAI-1 production by ADSC from patients with CAD and DM2 increased compared to the control group. PAI-1 gene expression in ADSC
(A) and protein concentration in ADSC conditioned medium (B) are presented. Data are median and percentiles (25-75%), p-values are presented on
the graphs. (C-D) Representative microphotographs of capillary-like tubes formed by EA.hy 926 endothelial cell line on Matrigel in the presence of
ADSC conditioned media (patient with CAD) with (C) or without (D) PAI-1 neutralizing antibodies (5 mkg/ml). (E) Total capillary-like tubes length
measurement in the presence of PAI-1 neutralizing antibodies (5 ug/ml) in ADSC conditioned medium to the standard condition (without antibodies).
Data are median and percentiles (25-75%), p-value is presented on the graph.
Dzhoyashvili et al. Journal of Translational Medicine 2014, 12:337 Page 9 of 13
http://www.translational-medicine.com/content/12/1/337
Dzhoyashvili et al. Journal of Translational Medicine 2014, 12:337 Page 10 of 13
http://www.translational-medicine.com/content/12/1/337such as cardiovascular diseases and metabolic disorders on
human ADSC. In the current study we analyzed ADSC ob-
tained from patients with CAD and T2DM and assess how
the disease itself could affect the properties of ADSC. It
should be emphasized that we investigated namely ADSC
as a promising tool for cell therapy, because these cells
could be more easily and safer isolated from patients and
considerably larger amounts of MSC could be obtained
from adipose tissue compared to other sources of MSC
such as bone marrow, etc. [28-30]. There is also some
evidence that ADSC have a higher angiogenic and immu-
nomodulatory capacities than bone marrow MSC and may
be more suited for some clinical applications [30-32].
It should be noted that widespread risk factors asso-
ciated with CAD (age, dislipidemia, obesity, smoking,
arterial hypertension, glucose intolerance) may have an
impact to the decrease of number and/or functional ac-
tivity of stem and progenitor cells [33-36]. Previously we
demonstrated that ADSC from aged patients with CAD
keep MSC properties but exhibit age markers and have
an impaired angiogenic potential [37]. Among the pa-
thologies affecting the functionality of stem and proge-
nitor cells some autoimmune diseases could be named
such as systemic sclerosis and systemic lupus [38].
According to the results of several studies MSC num-
ber is unlikely decreased in patients with cardiovascular
and metabolic diseases (such as T2DM), but their rege-
nerative potential is essentially attenuated. Thus, Harris
et al. [39] showed that number of ADSC obtained from
50 patients with different vascular pathologies was rela-
tively consistent independently of age and comorbidities
like obesity, T2DM, etc. [39]. Similar results were ob-
tained by Madonna et al. [36] on the 42 patients with
different grade of cardiovascular risk [36]. It was demon-
strated that ADSC isolated from adipose tissue of pa-
tients with T2DM had lower proliferation activity and
less responsive to the proangiogenic stimuli such as hy-
poxia [40]. In patients with obesity impaired differen-
tiation potential of ADSC and decline of their ability to
stimulate blood vessel growth were observed [41]. In the
study performed by Vecellio et al. [42] MSC obtained
from heart tissue of patients with T2DM were characte-
rized by a reduced proliferation rate, diminished phos-
phorylation at histone H3 serine 10 (H3S10P), decreased
differentiation potential, and premature cellular senes-
cence compared to the control group [42].
In our study we showed that ADSC from the patients
with CAD and CAD+DM had similar morphology and
immunophenotype, preserved adipogenic and osteogenic
differentiation potency, higher proliferation activity, but
shorter telomeres than ADSC from the patients in the
control group. Telomere shortening is often considered as
a marker of replicative senescence of cells expanded
in vitro, but in our study culture conditions and durationwere similar for all samples, so we could assume that dif-
ferences in relative telomere length were caused by
patient-related factors. It might reflect the depletion of
progenitor cell compartment in the presence of chronic
pathologies such as CAD and T2DM.
Analyzing ADSC as a tool for therapeutic angiogenesis
we found that angiogenic activity in vitro of ADSC ob-
tained from patients with CAD and with CAD + T2DM
decreased compared to the patients without established
cardiovascular pathologies independently of such factors
as age and gender. As paracrine mechanism is consi-
dered to be the main regulator of the beneficial effects
of ADSC we examined the ability of ADSC to secrete
some key angiogenic and antiapoptotic growth factors.
Interestingly, we found that the level of VEGF, a critical
vascular regulator, and important proangiogenic factor
HGF secreted by ADSC were significantly higher for pa-
tients with CAD, as well as HGF and PlGF for patients
with CAD + T2DM compared to the control group.
Taking onto account that process of angiogenesis de-
pends on the intricate balance between angiogenic and
angiostatic factors, we speculated that the main cause of
impaired in vitro angiogenic activity of ADSC obtained
from patients with CAD and CAD + T2DM was the in-
creased level of the angiogenesis inhibitors. We showed
that gene expression of THBS-1, an inhibitor of angio-
genesis through the direct effects on endothelial cell mi-
gration, proliferation, survival and apoptosis as well as
by antagonizing the activity of VEGF [43], is significantly
increased in ADSC from patients with CAD and CAD +
T2DM. However, we couldn’t confirm this finding on
the protein level pointing that some indirect mecha-
nisms of THSP-1 participation in the angiogenic effects
of ADSC could be discussed.
Analyzing the expression of factors involved in ECM
remodeling and vascular cell migration and invasion we
revealed that mRNA level of PAI-1 as well as its secre-
tion by ADSC were significantly increased in groups of
patients with CAD and CAD + T2DM. PAI-1 is one of
the primary regulators of the fibrinolytic system, and it
has a crucial effect on cell migration and adhesion. It
was shown that high level of PAI-1 is linked with high
risk of CAD, diabetes and obesity. PAI-1 can both pro-
mote and inhibit vascular remodeling, but its role in
angiogenesis and tissue regeneration is still controversial.
It may be presumed that the balance between these two
mechanisms depends on a disease state. Plasma PAI-1 is
closely correlated with such factors as hypoxia, glucose-
related signaling molecules, inflammatory cytokines, tria-
cylglycerol and insulin [44-46]. Acosta et al. [47] showed
that ADSC obtained from patients with T2DM have less
fibrinolytic ability as they secreted more PAI-1 and less
tissue activator of plasminogen and D-dimer, which leads
to the development of microtrombotic complications of
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low limb ischemia [47]. PAI-1 actively interacts with uPA,
an important factor of extracellular proteolysis, which not
only specifically cleaves plasminogen and converts it into
plasmin particularly causing different MMPs activation
but also initiates intracellular signaling upon binding to its
receptor on the cell surface and therefore plays a multiple
role in vascular remodeling and angiogenesis. uPA system
play an essential role in growth factor-induced endothelial
cell migration and invasion. uPA gene transfer effectively
induces functionally significant angiogenesis in models of
acute MI and hind limb ischemia [48]. We suppose that
PAI-1 produced by ADSC exerted anti-angiogenic effect
also through the inhibition of uPA.
Importantly, we demonstrated that by neutralizing only
one factor in ADSC conditioned medium – PAI-1 – one
could partially restore the angiogenic activity of ADSC ob-
tained from patients with chronic diseases. Our data are
corroborated by the results obtained by Tashiro et al. [49]
who have showed that PAI-1 inhibition in vivo under
ischemic conditions increases the pro-angiogenic factor
activity such as VEGF-A and FGF-2 and leads to the
angiogenesis stimulation and improvement of tissue per-
fusion restoration [49].
It should be noted that we didn’t see any statistically sig-
nificant evidence that T2DM had an additional impact to
the decline of ADSC angiogenic activity in vitro when
combined with CAD. There are numerical studies demon-
strating that T2DM and particularly hyperglycemia as a
main pathogenic factor of diabetes seriously affect MSC
properties. Thus, impaired neovascular potential of ADSC
obtained from streptozotocin-induced and db/db diabetic
mice was demonstrated [50] as well as lower efficiency of
these cells in promoting wound healing [51]. T2DM at-
tenuated the capacity of MSC to promote neovasculari-
zation in the ischemic hindlimb which was secondary to
hyperinsulinemia-induced, Nox4-dependent oxidant stress
in db/db MSCs [52]. According to our data culturing of
human ADSC in hyperglycemic conditions affects the
ability of these cells to stimulate capillary-tube formation
by endothelial cells in vitro [53]. However, in patients with
CAD+T2DM the contribution of each disease to the
influence on ADSC properties was hard to determine.
Another issue was that ADSC isolated from patients with
hyperglycemia were cultured ex vivo in normoglycemic
conditions which could reverse some hyperglycemia-
related effects on ADSC and mask the influence of T2DM
on ADSC properties.
Considering the disease-associated dysfunction of ADSC
obtained from patients with cardiovascular and metabolic
pathologies one could make a conclusion that using allo-
geneic MSC from young healthy donors would be more
appropriate approach for cell therapy in these cohorts of
patients. However, there are some serious restrictions ofthis approach related to the immunogenicity and lack of
engraftment of transplanted allogeneic MSC [54]. In the
stem cell-based clinical trials both autologous and allo-
geneic cells are using in similar proportions [55] and there
is still no clear evidence which source is better for clinical
application.
We also have to highlight the necessity of extended
investigation of ADSC secretome with the special em-
phasis on the balance between pro- and anti-angiogenic
factors to characterize the individual angiogenic poten-
tial of ADSC obtained from patients, in particular, with
cardiovascular and metabolic pathologies. The results of
such studies will help to reveal some key factors (like
PAI-1) that should be controlled to access the potency
of autologous ADSC to stimulate angiogenesis. Another
important challenge is to find the most promising tar-
gets for the correction of ADSC angiogenic properties
before transplantation. ADSC could be easily modified
by gene constructions contained angiogenesis-related
factors, thus, VEGF-modified ADSC had significantly
stronger therapeutic effect on the model of hind limb is-
chemia [56]. According to the results of our study PAI-1
might be a potential target for modification to modulate
angiogenic activity of ADSC obtained from patients with
CAD and T2DM. Another approach includes a hypoxic
preconditioning as we showed that short-term hypoxia
promoted ADSC ability to stimulate angiogenesis by
coordinated changes in pro- and anti-angiogenic factor
secretion by these cells [57].Conclusions
Taken together we showed that ADSC angiogenic activity
is significantly declined in patients with CAD and T2DM,
which could restrict the effectiveness of autologous cell
therapy with ADSC in these cohorts of patients. According
to our data, this impairment might be due to the disturb-
ance in coordinated network of pro- and anti-angiogenic
growth factors secreted by ADSC. We observed several
changes in ADSC secretome between patients with CAD
and T2DM pointing the possible specific targets for modi-
fication of autologous ADSC obtained from patients with
different chronic pathologies to stimulate their regenerative
potential. However, further investigations are necessary to
reveal the MSC-involved mechanisms of cardiovascular
and metabolic diseases as well as to develop novel ap-
proaches to their correction using the methods of regen-
erative medicine.Additional files
Additional file 1: Table S1. Sequence of primers used for real-time PCR.
Additional file 2: Figure S1. Representative flow cytometry charts of
MSC surface markers expression on ADSC obtained from patients with
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Additional file 3: Figure S2. Representative flow cytometry charts of
pericyte surface markers expression on ADSC obtained from patients with
CAD, CAD+T2DM and control group. Red lines – specific antibodies, blue
lines – isotype antibodies.
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